Physician profile
Tushar Sharma
NPI 1689089385
$30,784.45
in general payments reported to CMS, 2019-2025
15 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.19 · 2020: $16.17 · 2021: $41.92 · 2022: $592 · 2023: $3,812 · 2024: $5,318 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $16K · Food and Beverage: $7,102 · Grant: $6,286 · Education: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $15,609.04 |
| Food and Beverage | $7,102.30 |
| Grant | $6,285.72 |
| Education | $1,083.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13,006.00 | 2023-2025 | Micra, Aurora Ev-Icd Mri Surescan, Affera Mapping System |
| Abbott Laboratories | $9,842.01 | 2022-2025 | Gallant, Cardiomems, Ensite Precision |
| Boston Scientific Corporation | $3,957.60 | 2023-2025 | General - Therapies, Versacross Connect Laac Access Solution |
| Biosense Webster, INC. | $3,172.45 | 2025 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $331.24 | 2019-2024 | Eliquis, Camzyos |
| Alnylam Pharmaceuticals INC. | $124.94 | 2022 | |
| Astellas Pharma US INC | $99.95 | 2023 | |
| Impulse Dynamics (USA) INC. | $56.64 | 2023 | Optimizer |
| Abiomed | $47.93 | 2024 | Impella |
| Heartflow, INC. | $39.48 | 2024 | |
| Pfizer INC. | $32.43 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.44 | 2024 | Lifevest |
| Livanova USA, INC. | $17.32 | 2023 | Protekduo |
| Astrazeneca Pharmaceuticals LP | $16.71 | 2025 | Wainua |
| Altathera Pharmaceuticals LLC | $14.31 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tushar Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.